NASDAQ:VOR Vor Biopharma Q3 2026 Earnings Results & Report $19.64 -1.27 (-6.09%) As of 12:47 PM Eastern This is a fair market value price provided by Massive. Learn more. Vor Biopharma missed analyst earnings expectations in its Q3 2026 results, released October 30, 2026. The company reported EPS of -$1.45 versus the -$0.81 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateOctober 30, 2026TimeBefore Market OpensConference Call7:00 AM ET Vor Biopharma EPS ResultsActual EPS-$1.45Consensus EPS -$0.81Beat/MissMissed by -$0.64One Year Ago EPSN/AEPS Beat Rate1 of last 8 quartersVor Biopharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Vor Biopharma Q3 2026 Earnings FAQ Did Vor Biopharma beat earnings estimates for Q3 2026? Vor Biopharma (NASDAQ:VOR) reported earnings of -$1.45 per share for Q3 2026, missing the consensus estimate of -$0.81. The report was announced on Friday, October 30, 2026. Vor Biopharma Earnings HeadlinesVor Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update4 hours ago | globenewswire.comVor Bio Announces Final Two-Year Results From Phase 3 TELIGAN Trial Evaluating Telitacicept In Adults With IgA NephropathyOctober 23, 2026 | marketscreener.comMTwo charts tell you the future…Gold miners are posting record cash flows, outperforming every other sector, yet mining still makes up just 1% of global equities. Garrett Goggin, CFA, CMT, has spent more than 20 years studying gold cycles and mining companies. Porter Stansberry has called him the most knowledgeable gold investor in the world.October 30 at 1:00 AM | Golden Portfolio (Ad)Vor Biopharma Inc. (NASDAQ:VOR) Stock Now Rated "Moderate Buy" by Wall Street AnalystsOctober 23, 2026 | americanbankingnews.comWilliam Blair Begins Coverage on Vor Biopharma (NASDAQ:VOR)October 23, 2026 | americanbankingnews.comVor Bio says its experimental drug slowed loss of kidney function in late-stage studyOctober 22, 2026 | reuters.comSee More Vor Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Vor Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vor Biopharma and other key companies, straight to your email. Email Address About Vor BiopharmaVor Biopharma (NASDAQ:VOR) is a clinical-stage biotechnology company focused on developing engineered hematopoietic stem cell therapies for the treatment of cancer, particularly blood cancers. The company combines gene-editing technologies with targeted immunotherapies to address limitations associated with conventional cancer treatments. Vor’s platform is designed to create engineered hematopoietic stem cells that can protect healthy blood-forming cells from targeted therapies. Its lead program, VOR33, is an investigational CD33-edited hematopoietic stem cell therapy intended to support the use of CD33-targeted treatments in patients with acute myeloid leukemia. The company has also developed investigational CAR-T and other immune-based therapies directed at cancer targets. Vor Biopharma was founded in 2015 and is headquartered in Cambridge, Massachusetts. Its programs are being developed through clinical research and collaborations in the United States; as an early-stage biotechnology company, it does not operate a broad commercial product portfolio or established geographic sales network.View Vor Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Silicon Shock: Intel's 25% Valuation ResetBreaching the Valuation: The Real Reason Fortinet DroppedMicrosoft Earnings Expose a Growing Divide in the Magnificent 7 AI TradeWhere's the Beef? Trian-Led Buyout Proposal Values Wendy's at $1.4B, But Is It Enough?Chipotle's $32 Floor: Is a Major Stock Rebound Coming?SaaS-Pocalypse II: Is ServiceNow's Sell-Off Another Buying Opportunity?Alphabet’s Cloud Is Paying Off—But the Bill for Building It Keeps Growing Upcoming Earnings Marriott International (11/2/2026)Diamondback Energy (11/2/2026)Williams Companies (11/2/2026)Vertex Pharmaceuticals (11/2/2026)Realty Income (11/2/2026)Apple (11/2/2026)Palantir Technologies (11/2/2026)Entergy (11/2/2026)Booking (11/3/2026)Ferrari (11/3/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
